AVEO Oncology (AVEO) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
August 5, 2021 4:05 PM EDTTotal 2Q 2021 Revenue of $7.6 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $6.7 Million
Pivotal Phase 3 TiNivo-2 Trial of FOTIVDA in Combination with OPDIVO® (nivolumab) on Track to Initiate Enrollment in 3Q 2021
COVID-19 Related Manufacturing Supply Shortages to Push Potential Registrational Study Start for Ficlatuzumab to 2023
Company to Host Conference Call Today at 4:30 p.m. ET
BOSTON--(BUSINESS WIRE)-- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the... More
